Office of Immunology and Inflammation - Division of Gastroenterology (DG)
The Division of Gastroenterology (DG) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products intended for the prevention, treatment or diagnosis of gastrointestinal conditions including:
- Inflammatory bowel disease
- Irritable bowel syndrome
- Gastroesophageal reflux disease/erosive esophagitis
- Duodenal/Gastric ulcers
- Celiac disease
- Eosinophilic gastrointestinal diseases
- Motility disorders, including gastroparesis
- Constipation
- Bowel cleansing agents
- Anorectal disorders
- Anti-diarrheal agents
- Anti-emetics (chemotherapy-induced or postoperative nausea and vomiting)
- Short bowel syndrome
- Pancreatic agents
Special Procedures for Physician Requests for Domperidone
Director: Jessica J. Lee, MD, MMSc
Deputy Director: Juli Tomaino, MD, MS
Deputy Director for Safety: Joyce Korvick
Division Director of Pharm/Tox for Immunology and Inflammation: Andrew Goodwin (Acting)
Regulatory Operations
Chief, Project Management Staff: Richard Whitehead, MS
Contact Us
Mailing Address:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Gastroenterology
10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4177
Phone: (301) 796-2120
Fax: (301) 796-9838
Resources For You
- Office of Immunology and Inflammation
- Office of New Drugs
- CDER Offices and Divisions
- Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality